Drug · DIN 02458071
VYVANSE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since July 26, 2021; first marketed January 5, 2017.
- Drug Identification Number (DIN)
- 02458071
- Company (DIN owner)
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Schedule
- Controlled drugs (cdsa i)
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Lisdexamfetamine N06BA12
- Class
- Human
- Record last updated
- October 16, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LISDEXAMFETAMINE DIMESYLATE | 70 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 23, 2020: NOC 23943New Drug Submission (NDS) · Administrative: Merger/Buy-out
- September 30, 2016: NOC 18545Supplement to a New Drug Submission (SNDS) · New 70 mg strength for the treatment of binge eating disorder in adults. new indication for the 30, 50, 70 mg strengths for the treatment of binge eating disorder in adults
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “vyvanse”. A notice may cover another product or only some lots: read it to see what it covers.
- Vyvanse Capsule (2019-08-08)August 8, 2019 · Drugs · Product safety · Type III
Other DINs named VYVANSE
- DIN 02322951 · Marketed
- DIN 02322978 · Marketed
- DIN 02347156 · Marketed
- DIN 02347164 · Marketed
- DIN 02347172 · Marketed
- DIN 02439603 · Marketed
- DIN 02490226 · Marketed
- DIN 02490234 · Marketed
- DIN 02490242 · Marketed
- DIN 02490250 · Marketed
- DIN 02490269 · Marketed
- DIN 02490277 · Marketed